Australian Clinical Labs at 6-month high on upbeat full-year results, guidance

Australian Clinical Labs

17/08/2026 06:11

** Shares of Australian Clinical Labs ACL.AX rise as much as 21.7% to A$2.86, highest level since February 3
** Set to log its best session ever, if trend holds
** Pathology services provider reports FY underlying net profit of A$35.2 million ($25.00 million), up 4.6% on pcp
** ACL declares final dividend of 9.25 Australian cents per share compared to 9 Australian cents a year ago 
** Expects FY27 revenue of A$745 million to A$765 million, up from A$735.8 million in FY26, and underlying EBIT between A$67 million to A$73 million compared to A$69.2 million in FY26
** About 3.5 million shares change hands, 6.5 times the 30-day avg
($1 = 1.4081 Australian dollars)

 (Reporting by Anjali Singh in Bengaluru)
 ((anjali.singh2@thomsonreuters.com;))